Information Provided By: 
Fly News Breaks for January 28, 2020
XLRN
Jan 28, 2020 | 07:27 EDT
Cowen analyst Yaron Weber raised his price target on Acceleron to $109 from $78 following its positive Phase 2 PULSAR sotatercept data in PAH. The data was surprising given its low expectations and exceeded expectations in a heavily pre-treated population meeting both primary and secondary endpoints. The analyst sees $559M in peak sotatercept sales. Weber reiterated his Outperform rating.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
